

1. **Advisory Committee** of the International **Autologous** Bone Marrow Transplant Registry, "Autologous Bone Marrow Transplants: Different Indications in Europe and North America," *Lancet* 11(8658):317-318, Aug. 5, 1989.
2. *American Journal of Hospital Pharmacy*, Questions and Answers Column, 'Reimbursement for Immunosuppressive Drug Products,' 44:2005-2008, September 1987.
3. American Medical Association, Group on Health Policy, personal communication, Chicago, IL, January 1991.
4. American Society of Transplant Surgeons, 'Survey on Present Status of Reimbursement for Immunosuppressive Drugs,' Houston, TX, 1990.
5. **Aronoff, R.**, U.S. Department of Health and Human Services, Public Health Service, Health Resources and Services Administration, Bureau of Health Resources Development, Division of Organ Transplantation, personal communications, November 1990-January 1991.
- 5a. **Baker, C.**, and **Kramer, N.**, "Employer-Sponsored Prescription Drug Benefits," *Monthly Labor Review* 114(2):31-34, February 1991.
6. Based on a review of the scientific literature performed by **Battelle** and reported in **Battelle** Human Affairs Research Centers, Seattle, Washington, *Cost and Outcome Analysis of Kidney Transplantation; The Implications of Initial Immunosuppressive Protocol and Diabetes*, under agreement with the Health Care Financing Administration, Cooperative Agreement 14-C-98564/0, August 1989.
7. **Battelle** Human Affairs Research Centers, Seattle, Washington, *Cost and Outcome Analysis of Kidney Transplantation; The Implications of Initial Immunosuppressive Protocol and Diabetes*, under agreement with the Health Care Financing Administration, Cooperative Agreement 14-C-98564/0, August 1989.
8. **Block, R.**, Blue Cross/Blue Shield Association, Chicago, IL, personal communication, Mar. 29, 1991.
9. **Bochinno, Carmella**, *Nursing Economics*, Legislative Services Division, Washington, DC, personal communication, Apr. 9, 1991.
10. **Bond, R. S.**, and **Lean, D.F.**, "Sales, Promotion and Product Differentiation in Two Prescription Drug Markets," staff report to the Federal Trade Commission, Washington, DC, 1977.
11. "Bone Marrow Autotransplantation in Man," Report of an International Cooperative Study, *Lancet*, Oct. 25, 1986, pp. 960-962.
12. **Bortin, M.M.**, and **Rimm, A.A.**, "Increasing Utilization of Bone Marrow Transplantation, Results of the 1985-1987 Survey," *Transplantation* 48(3):453-458, September 1989.
13. **Buco, M.**, Blue Cross/Blue Shield Association, Chicago, IL, personal communication, November 1990.
14. Cancer Information Center, National Cancer Institute, Bethesda, MD, personal communication, June 1991.
15. **Debure, A.**, **Chkoff, N.**, **Chatenoud, L.**, et al., "One-Month Prophylactic Use of OKT-3 in Cadaver Kidney Transplant Recipients," *Transplantation* 45 (3):546-553, March 1988.
16. **Dunn, J.**, **Golden, D.**, **Van Buren, C.T.**, et al., "Causes of Graft Loss Beyond Two Years in the Cyclosporine Era," *Transplantation* 49(2):349-353, February 1990.
17. **Eggers, P.W.**, Chief, Program Evaluation Branch, Office of Research, Health Care Financing Administration, Baltimore, MD, personal communications, 1990 and 1991.
18. **Eggers, P.W.**, "The Medicare Experience With End-Stage Renal Disease: Trends in Incidence, Prevalence, and Survival," *Health Care Financing Review* 5(3):69-88, 1984.
19. **Engemann, R.**, **Gassel, H.J.**, **LaFrenz, E.**, et al., "The Use of 15-Deoxyospergualin in Orthotropic Rat Liver Transplantation," *Transplant Procedures* 20(1): 237-239 (SUP@. 1), 1988.
20. **Ford, M.**, "Medicaid: Reimbursement for Outpatient Prescription Drugs," U.S. Congress, Congressional Research Service, Washington, DC, March 1991.
21. **Held, P.W.**, Senior Economist, The Urban Institute, Washington, DC, personal communication, Jan. 10, 1991.
22. **Hellinger, F.J.**, "Status of Insurance Coverage for Organ Transplants in the United States: A Review of Recent Surveys," *International Journal of Technology Assessment in Health Care* 2:563-570, 1986.
23. **Henry, F. C.**, **Kootee, A.M.M.**, **Van Bockel, J.H.**, et al., "A Prospective Study on the Influence of Cyclosporine and Azathioprine on Renal Allograft Survival and Function," *Transplant Procedures* 19:1853-1955, 1987.
24. **Hohman, R.**, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, personal communication, January 1991.

25. **Hull**, A.R., Dallas Nephrology Associates, Dallas, TX, personal communication, 1991.
26. Intergovernmental Health Policy Project, George Washington University, Washington, DC, *Medicaid Coverage and Payment of ESRD Services*, under contract to the Institute of Medicine, ESRD Study Committee, July 6, 1990.
27. Intergovernmental Health Policy Project, George Washington University, Washington, DC, *Medicaid Coverage and Payment Policies for Organ Transplants: Findings of a National Survey*, prepared for the U.S. Department of Health and Human Services, Health Resources and Services Administration, Contract No. HRSA 88-457, November 1988.
28. **Kahan**, B.D., Director, Division of Immunology and Organ Transplantation, University of Texas Medical School, Houston, TX, personal communication, November 1990.
29. **Kahan**, B. D., "The Impact of CSA Therapy," *Transplantation and Immunology Letter* 4(4):15, 1988.
30. **Kasiske**, B.L., **Neylan III**, J.F., **Riggio**, R.R., et al., "The Effect of Race on Access and Outcome in Transplantation," *New Eng. J. Med.*, 324:302-307, Jan. 31, 1991.
31. **Laudicina**, Susan S., Intergovernmental Health Policy Project, George Washington University, Washington, DC, personal communication, January 1991.
32. **Light**, J., Washington Hospital Center, Washington, DC, personal communication, Nov. 19, 1990.
33. **Macleod**, A.M., and **Thomson**, A.W., "FK-506: An Immunosuppressant for the 1990s?" *Lancet* 337 (8732):25-27, Jan. 5, 1991.
34. **McCullough**, S., **IMS America**, Plymouth, PA, personal communications, Jan. 2, 1991.
- 34a. Medical Economics Data, *Drug Topics Red Book 1991* (Oradell, NJ: Medical Economics Co., Inc., 1991).
35. North American Autologous Bone Transplant Registry, University of Nebraska, Lincoln, NE, personal communication with J. Armitage, December 1990.
36. Physician Payment Review Commission, *Annual Report to Congress, 1990* (Washington, DC:PPRC, 1990).
37. Prospective Payment Assessment **Commission**, *Medicare Prospective Payment and the American Health Care System* (Washington, DC: PropAC, June 1988).
38. **Rettig**, R., The Institute of Medicine, *ESRD Study*, Washington, DC, personal communication, December 1990.
39. **Scheaffer**, L., U.S. Department of Health and Human Services, Health Resources and Services Administration, **Rockville**, MD, personal communication, April 1991.
40. **Schemer**, U., **Vissing**, S.F., **Morgan**, B.J., et al., "Cyclosporine-Induced Sympathetic Activation and Hypertension After Heart Transplantation," *New Eng. J. Med.* 323(11):693-699, Sept. 13, 1990.
41. **Schulak**, J.A., and **Corry**, R.J., "Manipulation of the Immune Response: Other Methods," in **Cerrilli**, G.J. (cd.), *Organ Transplantation and Replacement* (New York, NY: J.B. Lippincott Co., 1988), pp. 137-150.
42. **Showstack**, J., **Katz**, P., **Arneud**, W., et al., "The Association of Cyclosporine With the 1-Year Costs of Cadaver-Donor Kidney Transplants," *J.A.M.A.* 264(14):1818-1823, Oct. 10, 1990.
43. **Sisk**, J.E., **Cook-Deegan**, R., **Dougherty**, D., et al., *The Use of Immunosuppressive Drugs in Kidney Transplantation—Staff Paper* (Washington, DC: Office of Technology Assessment, March 1984).
44. **St. Collier**, J.D., **Caine**, R., **Thiru**, S., et al., "15-Deoxyspergualin in Experimental Dog Renal Allografts," *Transplant Procedures* 10(1):240-241 (suppl. 1), 1988.
45. **Starzl**, T.E., **Fung**, J., **Jordan**, M., et al., "Kidney Transplantation Under FK-506," *J.A.M.A.* 264(1):63-67, July 4, 1990.
46. **Tilney**, N.L., and **Strom**, T.B., "Chemical Manipulation of the Immune Responses," in **Cerrilli**, G.J. (cd.), *Organ Transplantation and Replacement* (New York, NY: J.B. Lippincott Co., 1988), pp. 118-136.
47. **Todo**, S., **Murase**, N., **Ueda**, Y., et al., "Effect of FK-506 in Experimental Organ Transplantation," *Transplant Procedures* 20(1):233-236 (suppl. 1), 1988.
48. U.S. Congress, Congressional Research Service, *Medicaid Source Book: Background Data and Analysis* (Washington, DC: U.S. Government Printing Office, November 1988).
49. U.S. Congress, House of Representatives, Committee on Energy and Commerce, Subcommittee on Health and the Environment, hearing on payment for outpatient immunosuppressive drugs for transplant recipients, Washington, DC, Nov. 14, 1983.
50. U.S. Congress, House of Representatives, **Committee** on Energy and Commerce, Subcommittee on Health and the Environment, "Second Staff Report on Price Increases for Prescription Drugs and Related Information," Washington, DC, Apr. 21, 1987.
51. U.S. Congress, Office of Technology Assessment, *Medical Technology and Costs of the Medicare Program*, **OTA-H-227** (Washington, DC: Office of Technology Assessment, July 1984).
52. U.S. Department of Health and Human Services, Health Care Financing Administration, "Blood

- Platelet Transfusions and Bone Marrow Transplantation,' Chapter 11-Coverage Issues Appendix, Medicare Coverage Issues Manual, **HCFA** Pub. No. 6, Baltimore, MD, June 1985.
53. U.S. Department of Health and Human Services, Health Care Financing Administration, Bureau of Data Management and Strategy, *Annual Medicare Program Statistics*, **HCFA** Pub. No. 03282 (Baltimore, MD: U.S. **DHHS**, June 1989).
 54. U.S. Department of Health and Human Services, Health Care Financing Administration, Bureau of Policy Development, Division of Dialysis and Transplant Payment Policy, "Coverage of Transplants Under Medicare," unpublished staff paper, Baltimore, MD, Nov. 28, 1990.
 55. U.S. Department of Health and Human Services, Health Care Financing Administration, Office of Payment Policy, Division of Special Payment Programs, "Medicare Payment for Immunosuppressive Drugs," unpublished staff paper, Baltimore, MD, Sept. 24, 1990.
 56. U.S. Department of Health and Human Services, Health Care Financing Administration, "Payment for Immunosuppressive Drugs Furnished to Transplant Patients," section 5249, Reasonable Charges, Medicare Coverage Issues Manual, April 1990.
 57. U.S. Department of Health and Human Services, **Health** Care Financing Administration, *Research Report: End-Stage Renal Disease*, Baltimore, MD, various years series.
 58. U.S. Department of Health and Human Services, Office of Inspector General, *The Distribution of Organs for Transplantations: Expectations and Practices*, **OEI-01-89-00550**, draft report, August 1990.
 59. U.S. Department of Health and Human Services, Public Health Service, Task Force on Organ Transplantation, *Report to the Secretary and the Congress on Immunosuppressive Therapies* (**Rockville, MD**: U.S. **DHHS**, 1985).
 60. U.S. Department of Health and Human Services, public Health Service, Health Resources and Services Administration, Bureau of Health Resources Development, Division of Organ Transplantation, *Annual Report on the U.S. Scientific Registry for Organ Transplantation and the Procurement and Transplantation Network, 1988 & 1989*, contract Nos. 240-87-0069 and 240-87-0063 (Washington, DC: **HRSA**, 1990).
 61. U.S. Department of Health and Human Services, Public Health Service, Health Resources and Services Administration, Report of the Task Force on Organ Transplantation, *Organ Transplantation: Issues and Recommendations*, April 1986.
 62. **Waldoch** Koser, D., Data Administrator, International Bone Marrow Transplant Registry, Medical College of Wisconsin, Milwaukee, WI, personal communication, Dec. 14, 1990.
 63. **Zevi**, A., Duquesnoy, R., Eiras, G., et al., "In Vitro Effects of **FK-506** in Combination With Other Drugs," *Transplant Procedures* 20(1):220-222 (suppl. 1), 1988.